Morphosys makes equity-linked debut with €325m convert

Aidan Gregory

October 13, 2020 04:30 pm

Morphysis_PA_575_375 — Juliane Bengsch preparing probes for an analysis with a mass spectrometer in a biochemical lab of the biotech company Centogene at the Biomedical Research Centre in Rostock, Germany, 17 August 2016. The company founded ten years ago employs more than 300 international workers, mainly for the diagnosis of rare hereditary diseases. On 23 August 2016, the cornerstone for the new company headquarters at the harbour of Rostock will be layed. PHOTO: BERND WUESTNECK/dpa | Bernd Wüstneck/DPA/PA Images

Morphosys, the German biotech company, has tapped the equity-linked market with a new €325m convertible bond, adding to the flood of issuance from the sector during the pandemic.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Germany Health and Biotech Equity Europe EMEA SRI Goldman Sachs Equity-Linked

AG

Aidan Gregory